Skip to search formSkip to main contentSkip to account menu

BI 10773

Known as: BI-10773, BI10773 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

empagliflozin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus.
BI-10773, being developed by Boehringer Ingelheim Corp, is a sodium-glucose cotransporter (SGLT)2 inhibitor for the oral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)